查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593746

重度憂鬱症市場評估：按藥物類別、分銷管道和地區劃分的機會和預測（2017-2031）

Major Depressive Disorder Market Assessment, By Drug Classes, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 228 Pages | 商品交期: 3-5個工作天內

價格

全球重度憂鬱症 (MDD) 市場規模預計將從 2023 年的 122.5 億美元成長到 2031 年的 166.8 億美元，預測期內複合年增長率為 3.93%。

重度憂鬱症是一種常見且嚴重的精神疾病，其特徵是持續悲傷、絕望感以及對日常活動缺乏興趣或樂趣。它還會影響您的睡眠、食慾和整體功能。治療選擇包括心理治療（如認知行為療法）、抗憂鬱藥物如選擇性血清素再攝取抑制劑（SSRIs）和血清素去甲腎上腺素再攝取抑制劑（SNRIs）以及生活方式改變（如運動和營養）等。在某些情況下，可以使用經顱磁刺激（TMS）和電驚厥療法（ECT）等先進治療方法。由於各種類型的發展，用於治療重度憂鬱症的藥物和醫療器材市場預計在預測期內將成長。增加市場投資、監管機構的舉措以及各利益相關者為提高市場成長率而共同努力也預計將在未來幾年帶來重大變化。

該報告調查了全球重度憂鬱症市場，並提供了市場定義和概述、市場規模趨勢和預測、各個細分市場/地區/主要國家的詳細分析、行業結構以及對市場成長的影響。分析、案例研究、競爭格局、主要公司簡介等

目錄

第1章 專案範圍與定義

第2章 研究方法

第3章 執行摘要

第4章 全球重度憂鬱症市場展望

  • 市場規模分析與預測
  • 市佔率分析/預測
    • 按藥物類別
    • 按分銷渠道
    • 按地區
    • 公司市場佔有率分析
  • 市場地圖分析

第5章 北美重度憂鬱症市場展望

  • 市場規模分析與預測
  • 市佔率分析/預測
  • 國家市場評估
    • 美國
    • 加拿大
    • 墨西哥

第6章歐洲重度憂鬱症市場展望

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 土耳其
  • 波蘭

第7章亞太地區重度憂鬱症市場展望

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第8章 南美洲重度憂鬱症市場展望

  • 巴西
  • 阿根廷

第9章 中東和非洲重度憂鬱症市場前景

  • 沙烏地阿拉伯
  • 阿聯酋
  • 南非

第10章 供需分析

第11章 進出口分析

第12章 價值鏈分析

第13章 波特五力分析

第14章 PESTLE分析

第15章價格分析

第16章 市場動態

  • 市場驅動力
  • 市場課題

第17章市場趨勢與發展

第18章法律與監管架構/創新

  • 臨床試驗
  • 監管審批
  • 管道概覽

第19章 專利情況

第20章案例研究

第21章 競爭格局

  • 前 5 名市場領導者的競爭矩陣
  • 前5名企業SWOT分析
  • 前10名企業現狀
    • Viatris Inc.
    • AbbVie Inc.
    • Abbott Laboratories
    • Aurobindo Pharma, Inc.
    • Teva Pharmaceuticals, Inc.
    • Sun Pharmaceuticals Industries Ltd.
    • Pfizer Inc.
    • Eli Lilly and Company
    • Otsuka Pharmaceutical Co., Ltd.
    • Takeda Pharmaceuticals Company Limited

第22章 戰略建議

第23章 關於我們公司/免責聲明

Product Code: MX12258

Global major depressive disorder market stood at USD 12.25 billion in 2023 and is expected to reach USD 16.68 billion by 2031, growing at a CAGR of 3.93% during the forecast period. Major depressive disorder is a common and serious mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. It can affect sleep, appetite, and overall functioning. Treatment options include psychotherapy (such as cognitive-behavioral therapy), antidepressant medications like Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), and lifestyle changes (including exercise and nutrition). In some cases, advanced treatments like transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT) may be considered resistant cases. The market for pharmaceuticals and medical devices used to treat MDD is anticipated to grow during the forecast period due to various types of development, such as growing emphasis and clinical implications around mental health. Along with that, growing investments in the market, regulatory initiatives, and combined efforts of various stakeholders to boost the market's growth rate are anticipated to make huge changes in the future.

In August 2023, Biogen Inc. and Sage Therapeutics, Inc. announced the approval of ZURZUVAE (zuranolone) 50 mg by the US Food and Drug Administration (FDA). This medication is designed to treat postpartum depression (PPD) in adults. ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can rapidly improve depressive symptoms in women with PPD. Additionally, the FDA has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for zuranolone in the treatment of adults with major depressive disorder.

Biogen Inc. and Sage Therapeutics, Inc. announced the approval of ZURZUVAE (zuranolone) 50 mg by the US Food and Drug Administration (FDA). This medication is designed to treat postpartum depression (PPD) in adults. ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can rapidly improve depressive symptoms in women with PPD. Additionally, the FDA has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for zuranolone in the treatment of adults with major depressive disorder.

Rising Cases and Emphasis on Mental Health to Boost Market Demand

Major depressive disorder cases have been on the rise recently, which tends to elevate market demand for mental health solutions. The new understanding of mental health issues today eliminates the stigma while encouraging more individuals to seek treatment. Healthcare providers and pharmaceutical companies tend to concentrate their efforts on innovative therapies and holistic approaches, including psychotherapy, digital health solutions, and new treatments. The COVID-19 pandemic has also increased mental health issues. The cases of reported depression are on the rise, and effective interventions require better programs for mental health. Government initiatives towards increasing mental health program funding have also helped fuel this growth. As there is more understanding about mental health, the demand for more tailored and accessible options for treatment will drive the market towards significant growth over the next few years.

For instance, according to an article published in Signal Transduction and Targeted Therapy Journal in February 2024, the prevalence of depression is increasing every year. Approximately 300 million people worldwide are affected by major depressive disorder, making it one of the leading causes of disability. In 2018, MDD ranked third in terms of disease burden according to the World Health Organization (WHO), and it is predicted to become the leading cause by 2030.

Government Initiatives to Major Depressive Disorder Drives Market Growth

With the increasing interest of investors in the treatment of major depressive disorder, business increases due to higher investment in research and development of new treatments, such as pharmaceuticals and digital health solutions. With increased innovation rates, this more rapidly delivers greater diversity and effectiveness in therapies as well as personalization of treatment. Companies respond to the increased demand by offering more products, while competition helps bring down costs, enhancing patient care access. In addition, investors tend to encourage collaboration between biotechnology firms, research institutions, and healthcare delivery systems, which maximizes resource sharing and enhances research. Investment in the issues of mental health increases public awareness of mental illness, and the stigmatism associated with the conditions is reduced. Therefore, more individuals can receive help with mental health disorders.

For instance, in July 2024, Autobahn Therapeutics, Inc., a biotech company established from a lab at Oregon Health & Science University, secured USD 100 million in private investment to develop treatments for neuropsychiatric disorders like major depressive disorder and bipolar depression. The funding will advance their pipeline of brain-penetrant small molecules, including a compound targeting major depressive and bipolar depression disorders, which affect over 27 million people in the United States.

Drug Segment Dominates with High Market Share

The dominance of the drug segment in the major depressive disorder market relates to its accessible treatments. The application areas of pharmacological treatments, especially antidepressants of the SSRIs and SNRIs class, are broad in this area. Accessibility is a contributing factor to relatively higher patient adoption rates. Novel drug developments continue to create new formulations and targeted therapy forms that optimize treatment options and attract investments. Moreover, the high prevalence of MDD calls for medication, as most of them are yet to be relieved from the debilitating symptoms. Additionally, medication has been considered the first-line treatment for most healthcare providers, especially in moderate to severe cases, leading to strong market penetration. Regulatory approvals in the market further fuel the growth of the market share of the drug segment.

For instance, in September 2023, Fabre-Kramer Pharmaceuticals Inc., a biopharmaceutical company dedicated to psychiatry and neurology treatments, announced the US FDA approval of its Exxua, a gepirone hydrochloride extended-release tablet intended for the treatment of major depressive disorders in adults. Exxua represents a new class of antidepressants; it is the first and only approved antidepressant with a novel mechanism of action that selectively targets the serotonin 1A receptor, a key regulator of mood and emotion.

North America Dominates Major Depressive Disorder Market

North America holds a dominant position in the major depressive disorder market due to several factors. Firstly, there is a high prevalence of depression, driven by increasing awareness and improved diagnosis, leading to more patients seeking treatment. The region boasts advanced healthcare infrastructure and access to a wide range of treatment options, including innovative therapies and medications. Significant investment in mental health research and development fosters the emergence of new and effective treatments. Major pharmaceutical companies are concentrated in North America, driving competition and innovation. The US FDA plays a crucial role by providing expedited approval pathways for new treatments, which enhances market responsiveness to emerging therapies.

In August 2024, Otsuka Precision Health, Inc. and Click Therapeutics, Inc. launched Rejoyn, the first prescription digital therapeutic for treating major depressive disorder symptoms. The US FDA approved it in March 2024, and it is available for adult patients with MDD aged 22 years and older who are on antidepressant medication. Patients can obtain a prescription for Rejoyn from their current provider or via a virtual consultation from Wheel Health, Inc. BlinkRx is the exclusive pharmacy provider for Rejoyn.

Future Market Scenario (2024-2031F)

Innovative novel drugs that are still in the development stages can expand the major depressive disorder market greatly by establishing innovative lines of treatment, such as efficiency and reduced side effects. Advances in new antidepressants, including fast-acting ketamine and psychedelic chemicals, also give hope to patients who are resistant to conventional treatment options. Such developments improve a patient's outcome and expand the treatment scope, thereby attracting funding and investment for research purposes. In addition, the rising wave of personalized medicine approaches that use genetic and biomarker information in tailoring treatments will further increase the precision of MDD interventions. More advanced innovations regarding understanding the disorder will lead to earlier diagnosis and effective management strategies. Every time a new treatment enters the market, it increases competition and lowers costs, making it available for wider patient populations.

For instance, in July 2024, Johnson & Johnson Services, Inc. submitted a supplemental New Drug Application (sNDA) to the US FDA. They are seeking approval for SPRAVATO (esketamine) CIII nasal spray as a monotherapy for adults with treatment-resistant depression (TRD). It's worth noting that nearly 30% of the estimated 280 million people worldwide living with major depressive disorder have TRD. TRD occurs when there is an inadequate response to two or more oral antidepressants during the same depressive episode.

Key Players Landscape and Outlook

The market for major depressive disorder is segmented into drugs mainly. The drug market is quite fragmented, with a huge number of players, while the device market is quite consolidated and has a lower share in terms of revenue. Recent market activities include mergers and acquisitions along with innovative product launches.

In August 2024, AbbVie Inc. completed its acquisition of Cerevel Therapeutics Holdings, Inc., enhancing its neuroscience portfolio, particularly in treating major depressive disorder (MDD). Cerevel's pipeline includes CVL-354, a potential kappa opioid receptor antagonist aimed at improving efficacy and tolerability for MDD. This acquisition aligns with AbbVie's strategy to address significant unmet needs in neurological and psychiatric conditions, promising advancements in therapies for patients suffering from these disorders.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Major Depressive Disorder Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Drug Class
      • 4.2.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
        • 4.2.1.1.1. Citalopram
        • 4.2.1.1.2. Escitalopram
        • 4.2.1.1.3. Fluoxetine
        • 4.2.1.1.4. Fluvoxamine
        • 4.2.1.1.5. Paroxetine
        • 4.2.1.1.6. Sertraline
      • 4.2.1.2. Selective Norepinephrine Reuptake Inhibitors (SNRIs)
        • 4.2.1.2.1. Desvenlafaxine Succinates
        • 4.2.1.2.2. Duloxetine
        • 4.2.1.2.3. Levomilnacipran
        • 4.2.1.2.4. Venlafaxine
        • 4.2.1.2.5. Bupropion
        • 4.2.1.2.6. Mirtazapine
        • 4.2.1.2.7. Trazodone
      • 4.2.1.3. Monoamine Oxidase Inhibitors (MAOIs)
        • 4.2.1.3.1. Phenelzine
        • 4.2.1.3.2. Tranylcypromine
        • 4.2.1.3.3. Antipsychotics
        • 4.2.1.3.4. Lithium Carbonate
        • 4.2.1.3.5. Aripiprazole
        • 4.2.1.3.6. Brexipiprazole
        • 4.2.1.3.7. Quetiapine
      • 4.2.1.4. Others
    • 4.2.2. By Distribution Channel
      • 4.2.2.1. Hospital Pharmacies
      • 4.2.2.2. Retail Pharmacies
      • 4.2.2.3. Online Pharmacies
    • 4.2.3. By Region
      • 4.2.3.1. North America
      • 4.2.3.2. Europe
      • 4.2.3.3. Asia-Pacific
      • 4.2.3.4. South America
      • 4.2.3.5. Middle East and Africa
    • 4.2.4. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Drug Class
    • 4.3.2. By Distribution Channel
    • 4.3.3. By Region

5. North America Major Depressive Disorder Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Class
      • 5.2.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
        • 5.2.1.1.1. Citalopram
        • 5.2.1.1.2. Escitalopram
        • 5.2.1.1.3. Fluoxetine
        • 5.2.1.1.4. Fluvoxamine
        • 5.2.1.1.5. Paroxetine
        • 5.2.1.1.6. Sertraline
      • 5.2.1.2. Selective Norepinephrine Reuptake Inhibitors (SNRIs)
        • 5.2.1.2.1. Desvenlafaxine Succinates
        • 5.2.1.2.2. Duloxetine
        • 5.2.1.2.3. Levomilnacipran
        • 5.2.1.2.4. Venlafaxine
        • 5.2.1.2.5. Bupropion
        • 5.2.1.2.6. Mirtazapine
        • 5.2.1.2.7. Trazodone
      • 5.2.1.3. Monoamine Oxidase Inhibitors (MAOIs)
        • 5.2.1.3.1. Phenelzine
        • 5.2.1.3.2. Tranylcypromine
        • 5.2.1.3.3. Antipsychotics
        • 5.2.1.3.4. Lithium Carbonate
        • 5.2.1.3.5. Aripiprazole
        • 5.2.1.3.6. Brexipiprazole
        • 5.2.1.3.7. Quetiapine
      • 5.2.1.4. Others
    • 5.2.2. By Distribution Channel
      • 5.2.2.1. Hospital Pharmacies
      • 5.2.2.2. Retail Pharmacies
      • 5.2.2.3. Online Pharmacies
    • 5.2.3. By Country Share
      • 5.2.3.1. United States
      • 5.2.3.2. Canada
      • 5.2.3.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Major Depressive Disorder Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Drug Class
          • 5.3.1.2.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
          • 5.3.1.2.1.1.1. Citalopram
          • 5.3.1.2.1.1.2. Escitalopram
          • 5.3.1.2.1.1.3. Fluoxetine
          • 5.3.1.2.1.1.4. Fluvoxamine
          • 5.3.1.2.1.1.5. Paroxetine
          • 5.3.1.2.1.1.6. Sertraline
          • 5.3.1.2.1.2. Selective Norepinephrine Reuptake Inhibitors (SNRIs)
          • 5.3.1.2.1.2.1. Desvenlafaxine Succinates
          • 5.3.1.2.1.2.2. Duloxetine
          • 5.3.1.2.1.2.3. Levomilnacipran
          • 5.3.1.2.1.2.4. Venlafaxine
          • 5.3.1.2.1.2.5. Bupropion
          • 5.3.1.2.1.2.6. Mirtazapine
          • 5.3.1.2.1.2.7. Trazodone
          • 5.3.1.2.1.3. Monoamine Oxidase Inhibitors (MAOIs)
          • 5.3.1.2.1.3.1. Phenelzine
          • 5.3.1.2.1.3.2. Tranylcypromine
          • 5.3.1.2.1.3.3. Antipsychotics
          • 5.3.1.2.1.3.4. Lithium Carbonate
          • 5.3.1.2.1.3.5. Aripiprazole
          • 5.3.1.2.1.3.6. Brexipiprazole
          • 5.3.1.2.1.3.7. Quetiapine
          • 5.3.1.2.1.4. Others
        • 5.3.1.2.2. By Distribution Channel
          • 5.3.1.2.2.1. Hospital Pharmacies
          • 5.3.1.2.2.2. Retail Pharmacies
          • 5.3.1.2.2.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Major Depressive Disorder Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Major Depressive Disorder Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Major Depressive Disorder Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Major Depressive Disorder Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Epidemiology and Patient Population

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals
  • 18.3. Pipeline Overview

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Viatris Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 21.3.2. AbbVie Inc.
    • 21.3.3. Abbott Laboratories
    • 21.3.4. Aurobindo Pharma, Inc.
    • 21.3.5. Teva Pharmaceuticals, Inc.
    • 21.3.6. Sun Pharmaceuticals Industries Ltd.
    • 21.3.7. Pfizer Inc.
    • 21.3.8. Eli Lilly and Company
    • 21.3.9. Otsuka Pharmaceutical Co., Ltd.
    • 21.3.10. Takeda Pharmaceuticals Company Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 3. Global Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 4. Global Major Depressive Disorder Market Share (%), By Region, 2017-2031F
  • Figure 5. North America Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 6. North America Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 7. North America Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 8. North America Major Depressive Disorder Market Share (%), By Country, 2017-2031F
  • Figure 9. United States Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. United States Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 11. United States Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 12. Canada Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 13. Canada Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 14. Canada Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 15. Mexico Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Mexico Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 17. Mexico Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 18. Europe Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 19. Europe Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 20. Europe Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Europe Major Depressive Disorder Market Share (%), By Country, 2017-2031F
  • Figure 22. Germany Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 23. Germany Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 24. Germany Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 25. France Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 26. France Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 27. France Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 28. Italy Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Italy Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 30. Italy Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 31. United Kingdom Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. United Kingdom Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 33. United Kingdom Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 34. Russia Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 35. Russia Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 36. Russia Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 37. Netherlands Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 38. Netherlands Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 39. Netherlands Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 40. Spain Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Spain Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 42. Spain Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 43. Turkey Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 44. Turkey Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 45. Turkey Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. Poland Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Poland Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 48. Poland Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 49. South America Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 50. South America Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 51. South America Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. South America Major Depressive Disorder Market Share (%), By Country, 2017-2031F
  • Figure 53. Brazil Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. Brazil Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 55. Brazil Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 56. Argentina Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Argentina Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 58. Argentina Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 59. Asia-Pacific Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 60. Asia-Pacific Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 61. Asia-Pacific Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 62. Asia-Pacific Major Depressive Disorder Market Share (%), By Country, 2017-2031F
  • Figure 63. India Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 64. India Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 65. India Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 66. China Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 67. China Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 68. China Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 69. Japan Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Japan Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 71. Japan Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 72. Australia Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 73. Australia Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 74. Australia Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 75. Vietnam Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 76. Vietnam Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 77. Vietnam Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 78. South Korea Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 79. South Korea Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 80. South Korea Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 81. Indonesia Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Indonesia Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 83. Indonesia Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 84. Philippines Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 85. Philippines Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 86. Philippines Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 87. Middle East & Africa Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 88. Middle East & Africa Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 89. Middle East & Africa Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 90. Middle East & Africa Major Depressive Disorder Market Share (%), By Country, 2017-2031F
  • Figure 91. Saudi Arabia Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 92. Saudi Arabia Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 93. Saudi Arabia Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. UAE Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. UAE Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 96. UAE Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 97. South Africa Major Depressive Disorder Market, By Value, In USD Billion, 2017-2031F
  • Figure 98. South Africa Major Depressive Disorder Market Share (%), By Drug Classes, 2017-2031F
  • Figure 99. South Africa Major Depressive Disorder Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. By Drug Classes Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 101. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 102. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023